Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG1113 in severe hemophilia
NCT05493631Phase 1Completed
- Sponsor
- GC Biopharma Corp
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MG1113 in hemophilia A and hemophilia B (HB) (3 cohorts), sponsored by GC Biopharma Corp. Primary endpoints: Adverse Events, Adverse Drug Reactions and 7 more. Started Aug 2022; status: completed.
02
Drugs
MG1113
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05493631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493631.